Table 1:
Patient characteristics.
| Cohort 1 | Cohort 2 | ||||
|---|---|---|---|---|---|
| Non-responder | Responder | Non-responder | Responder | ||
| n=15 | n=14 | n=13 | n=8 | ||
| Age | median | 68 | 62.5 | 64.5 | 63.5 |
| Range | 50–83 | 45–86 | 44–77 | 55–75 | |
| Gender | male | 6 | 8 | 10 | 5 |
| Female | 9 | 6 | 3 | 3 | |
| Race | Caucasian | 15 | 12 | 11 | 7 |
| African American | 0 | 2 | 2 | 1 | |
| Smoking history | current | 3 | 4 | 4 | 3 |
| former | 11 | 10 | 9 | 5 | |
| never | 1 | 0 | 0 | 0 | |
| pack year, average | 37.9 | 50.8 | 38.9 | 40.0 | |
| Performance status | 0 | 3 | 2 | 0 | 2 |
| 1 | 10 | 11 | 10 | 5 | |
| 2 | 2 | 1 | 3 | 1 | |
| Histology | adenocarcinoma | 9 | 7 | 6 | 4 |
| squamous cell | 6 | 5 | 5 | 1 | |
| adenosquamous | 0 | 1 | 0 | 0 | |
| NOS | 1 | 1 | 2 | 3 | |
| PD-L1 IHC* | positive | 5 | 6 | 2 | 5 |
| negative | 3 | 2 | 2 | 2 | |
| unknown | 7 | 6 | 9 | 1 | |
| EGFR | wild | 10 | 9 | 9 | 7 |
| uncommon | 1 | 0 | 0 | 0 | |
| exon19 deletion | 1 | 1 | 0 | 0 | |
| unknown | 3 | 4 | 4 | 1 | |
| ALK | wild | 11 | 10 | 9 | 7 |
| Unknown | 4 | 4 | 4 | 1 | |
| Stage | IIIB | 1 | 0 | 0 | 0 |
| IV | 14 | 14 | 13 | 8 | |
| Drug | nivolumab | 15 | 13 | 8 | 3 |
| Atezolizumab | 0 | 1 | 3 | 0 | |
| Pembrolizumab | 0 | 0 | 2 | 5 | |
*
Cases positive for PD-L1 had 1% or more tumor cells expressing PD-L1 by immunohistochemistry.
Abbreviation : NOS, not otherwise specified